Serum proteomics screening intercellular adhesion molecule-2 improves intermediate-risk stratification in acute myeloid leukemia
Background: The clinical risk classification of acute myelocytic leukemia (AML) is largely based on cytogenetic and molecular genetic detection. However, the optimal treatment for intermediate-risk AML patients remains uncertain. Further refinement and improvement of prognostic stratification are th...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2022-10-01
|
| Series: | Therapeutic Advances in Hematology |
| Online Access: | https://doi.org/10.1177/20406207221132346 |
| _version_ | 1811247947931713536 |
|---|---|
| author | Nan Zhang Xiaoyan Liu Jinxian Wu Xinqi Li Qian Wang Guopeng Chen Linlu Ma Sanyun Wu Fuling Zhou |
| author_facet | Nan Zhang Xiaoyan Liu Jinxian Wu Xinqi Li Qian Wang Guopeng Chen Linlu Ma Sanyun Wu Fuling Zhou |
| author_sort | Nan Zhang |
| collection | DOAJ |
| description | Background: The clinical risk classification of acute myelocytic leukemia (AML) is largely based on cytogenetic and molecular genetic detection. However, the optimal treatment for intermediate-risk AML patients remains uncertain. Further refinement and improvement of prognostic stratification are therefore necessary. Objectives: The aim of this study was to identify serum protein biomarkers to refine risk stratification in AML patients. Design: This study is a retrospective study. Methods: Label-free proteomics was used to identify the differential abundance of serum proteins in AML patients. Transcriptomic data were combined to identify key altered markers that could indicate the risk rank of AML patients. The survival status was assessed by Kaplan–Meier and multivariate Cox regression analyses. Results: We delineated serum protein expression in a population of AML patients. Many biological processes were influenced by the identified differentially expressed proteins. Association analysis of transcriptome data showed that intercellular adhesion molecule-2 (ICAM2) had a higher survival prediction value in the intermediate-risk AML group. ICAM2 was detrimental for intermediate-risk AML, regardless of whether patients received bone marrow transplantation. ICAM2 well distinguishes the intermediate group of patients, whose probability of survival is comparable to that of patients with the ELN-2017 according to the reference classification. In addition, newly established stratified clinical features were associated with leukemia stem cell scores. Conclusion: The inclusion of ICAM2 expression into the AML risk classification according to ELN-2017 was a good way to transfer patients from three to two groups. Thus, providing more information for clinical decision-making to improve intermediate-risk stratification in AML patients. |
| first_indexed | 2024-04-12T15:18:19Z |
| format | Article |
| id | doaj.art-588960e9fa6b48c0a52863fa16547179 |
| institution | Directory Open Access Journal |
| issn | 2040-6215 |
| language | English |
| last_indexed | 2024-04-12T15:18:19Z |
| publishDate | 2022-10-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Therapeutic Advances in Hematology |
| spelling | doaj.art-588960e9fa6b48c0a52863fa165471792022-12-22T03:27:33ZengSAGE PublishingTherapeutic Advances in Hematology2040-62152022-10-011310.1177/20406207221132346Serum proteomics screening intercellular adhesion molecule-2 improves intermediate-risk stratification in acute myeloid leukemiaNan ZhangXiaoyan LiuJinxian WuXinqi LiQian WangGuopeng ChenLinlu MaSanyun WuFuling ZhouBackground: The clinical risk classification of acute myelocytic leukemia (AML) is largely based on cytogenetic and molecular genetic detection. However, the optimal treatment for intermediate-risk AML patients remains uncertain. Further refinement and improvement of prognostic stratification are therefore necessary. Objectives: The aim of this study was to identify serum protein biomarkers to refine risk stratification in AML patients. Design: This study is a retrospective study. Methods: Label-free proteomics was used to identify the differential abundance of serum proteins in AML patients. Transcriptomic data were combined to identify key altered markers that could indicate the risk rank of AML patients. The survival status was assessed by Kaplan–Meier and multivariate Cox regression analyses. Results: We delineated serum protein expression in a population of AML patients. Many biological processes were influenced by the identified differentially expressed proteins. Association analysis of transcriptome data showed that intercellular adhesion molecule-2 (ICAM2) had a higher survival prediction value in the intermediate-risk AML group. ICAM2 was detrimental for intermediate-risk AML, regardless of whether patients received bone marrow transplantation. ICAM2 well distinguishes the intermediate group of patients, whose probability of survival is comparable to that of patients with the ELN-2017 according to the reference classification. In addition, newly established stratified clinical features were associated with leukemia stem cell scores. Conclusion: The inclusion of ICAM2 expression into the AML risk classification according to ELN-2017 was a good way to transfer patients from three to two groups. Thus, providing more information for clinical decision-making to improve intermediate-risk stratification in AML patients.https://doi.org/10.1177/20406207221132346 |
| spellingShingle | Nan Zhang Xiaoyan Liu Jinxian Wu Xinqi Li Qian Wang Guopeng Chen Linlu Ma Sanyun Wu Fuling Zhou Serum proteomics screening intercellular adhesion molecule-2 improves intermediate-risk stratification in acute myeloid leukemia Therapeutic Advances in Hematology |
| title | Serum proteomics screening intercellular adhesion molecule-2 improves intermediate-risk stratification in acute myeloid leukemia |
| title_full | Serum proteomics screening intercellular adhesion molecule-2 improves intermediate-risk stratification in acute myeloid leukemia |
| title_fullStr | Serum proteomics screening intercellular adhesion molecule-2 improves intermediate-risk stratification in acute myeloid leukemia |
| title_full_unstemmed | Serum proteomics screening intercellular adhesion molecule-2 improves intermediate-risk stratification in acute myeloid leukemia |
| title_short | Serum proteomics screening intercellular adhesion molecule-2 improves intermediate-risk stratification in acute myeloid leukemia |
| title_sort | serum proteomics screening intercellular adhesion molecule 2 improves intermediate risk stratification in acute myeloid leukemia |
| url | https://doi.org/10.1177/20406207221132346 |
| work_keys_str_mv | AT nanzhang serumproteomicsscreeningintercellularadhesionmolecule2improvesintermediateriskstratificationinacutemyeloidleukemia AT xiaoyanliu serumproteomicsscreeningintercellularadhesionmolecule2improvesintermediateriskstratificationinacutemyeloidleukemia AT jinxianwu serumproteomicsscreeningintercellularadhesionmolecule2improvesintermediateriskstratificationinacutemyeloidleukemia AT xinqili serumproteomicsscreeningintercellularadhesionmolecule2improvesintermediateriskstratificationinacutemyeloidleukemia AT qianwang serumproteomicsscreeningintercellularadhesionmolecule2improvesintermediateriskstratificationinacutemyeloidleukemia AT guopengchen serumproteomicsscreeningintercellularadhesionmolecule2improvesintermediateriskstratificationinacutemyeloidleukemia AT linluma serumproteomicsscreeningintercellularadhesionmolecule2improvesintermediateriskstratificationinacutemyeloidleukemia AT sanyunwu serumproteomicsscreeningintercellularadhesionmolecule2improvesintermediateriskstratificationinacutemyeloidleukemia AT fulingzhou serumproteomicsscreeningintercellularadhesionmolecule2improvesintermediateriskstratificationinacutemyeloidleukemia |